Comparison between ulinastatin and gabexate mesylate for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: A prospective, randomized trial

Journal of Gastroenterology

Volumn 42, Issue 2, 2007, Pages 161-167

  Ueki, Toshiharu ^a   Otani, Keisuke ^a   Kawamoto, Kenichiro ^a   Shimizu, Aiko ^a   Fujimura, Naruhito ^a   Sakaguchi, Seigo ^a   Matsui, Toshiyuki ^a  

^a Fukuoka University Chikushi Hospital   (Japan)

Author keywords

Endoscopic retrograde cholangiopancreatography; Gabexate mesylate; Pancreatitis; Post endoscopic retrograde cholangiopancreatography pancreatitis; Ulinastatin

Indexed keywords

GABEXATE MESILATE; MIRACRID; PANCREAS ENZYME; ULINASTATIN; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; FEMALE; HUMAN; HYPERAMYLASEMIA; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PANCREATITIS; PRIMARY PREVENTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE;

AGED; CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE; FEMALE; GABEXATE; GLYCOPROTEINS; HUMANS; MALE; MIDDLE AGED; PANCREATITIS; PROSPECTIVE STUDIES;

EID: 33947165306     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-006-1986-8     Document Type: Article

References (27)

1. T Yamamoto M Mori H Mimura K Hamazaki H Kashino A Gouchi 1991 Effects of gabexate mesylate (FOY) on the gallbladder, sphincter of Oddi and duodenum of the normal and gastrectomized dogs (abstract in English) J Smooth Muscle Res 27 87-96
2. V Di Francesco A Mariani G Angelini E Masci L Frulloni G Talamini 2002 Effects of gabexate mesylate, a protease inhibitor, on human sphincter of Oddi motility Dig Dis Sci 47 741-5 11991602 10.1023/A:1014775513616 1:CAS:528:DC%2BD38XjvFGntLw%3D
3. G Cavallini A Tittobello L Frulloni E Masci A Mariani V Di Francesco 1996 Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography N Engl J Med 335 913-23 10.1056/NEJM199609263351302
4. A Andriulli G Leandro G Niro A Mangia V Festa G Gambassi 2000 Pharmacologic treatment can prevent pancreatic injury after ERCP: A meta-analysis Gastrointest Endosc 51 1-7 10625786 10.1016/ S0016-5107(00)70377-4 1:STN:280:DC%2BD3c%2Fpt1OrtA%3D%3D
5. E Masci G Cavallini A Mariani L Frulloni PA Testoni S Curioni 2003 Comparison of two dosing regimens of gabexate in the prophylaxis of post-ERCP pancreatitis Am J Gastroenterol 98 2182-6 14572565 10.1111/ j.1572-0241.2003.07698.x 1:CAS:528:DC%2BD3sXot12itrc%3D
6. GS Xing SM Wu XW Zhang ZZ Ge 2006 Clinical trial of gabexate in the prophylaxis of post-endoscopic retrograde cholangiopancreatography pancreatitis Braz J Med Biol Res 39 85-90
7. T Tsujino Y Komatsu H Isayama K Hirano N Sosohiro N Yamamoto 2005 Ulinastatin for pancreatitis after endoscopic retrograde cholangiopancreatography: A randomized, controlled trial Clin Gastroenterol Hepatol 3 376-83 15822043 10.1016/S1542-3565(04)00671-8 1:CAS:528:DC%2BD2MXktVSisrw%3D
8. H Fujishiro K Adachi T Imaoka T Hashimoto N Kohge N Moriyama 2006 Ulinastatin shows preventive effect on post-endoscopic retrograde cholangiopancreatography pancreatitis in a multicenter prospective randomized study J Gastroenterol Hepatol 21 1065-9 16724996 10.1111/ j.1440-1746.2006.04085.x 1:CAS:528:DC%2BD28XntVylur8%3D
9. SY Chen JY Wang 2001 Ulinastatin in the treatment of acute pancreatitis: a multicenter clinical trial Chin J Dig Dis 21 293-6
10. PA Testoni F Bagnolo 2001 Pain at 24 h associated with amylase levels greater than 5 times the upper normal limit as the most reliable indicator of post-ERCP pancreatitis Gastrointest Endosc 53 33-9 11154486 10.1067/mge.2001.111390 1:STN:280:DC%2BD3M3gt1ehsw%3D%3D
11. PB Cotton G Lehman J Vennes JE Geenen RCG Russell WC Meyers 1991 Endoscopic sphincterotomy complications and their management: An attempt at consensus Gastrointest Endosc 37 383-93 2070995 1:STN:280:By6A3c7kt1M%3D
12. E Kaneko H Harada T Kasugai K Ogoshi H Tanba 2004 Complications from gastrointestinal endoscopy procedure from 1998 to 2002 (in Japanese) Gastroenterol Endosc 46 54-61
13. American Society for Gastrointestinal Endoscopy 2003 Complications of ERCP Gastrointest Endosc 57 633-8 10.1053/ge.2003.v57.amge030576633
14. T Otani 1998 Synthetic protease inhibitor for human acute pancreatitis (in Japanese) Nippon Shokakibyo Gakkai Zasshi 95 1205-11 9852723 1:STN:280:DyaK1M%2FmvFyhtw%3D%3D
15. S Takasugi N Toki 1980 Inhibitory effects of native and synthetic protease inhibitors on plasma proteases in acute pancreatitis Hiroshima J Med Sci 29 189-94 7009505 1:CAS:528:DyaL3MXhvVGntrs%3D
16. J Hirose T Ozawa T Miura M Isaji Y Nagao K Yamashiro 1998 Human neutrophil elastase degrades inter-α-trypsin inhibitor to liberate urinary trypsin inhibitor related proteins Biol Pharm Bull 21 651-6 9703243 1:CAS:528:DyaK1cXkslyjtbc%3D
17. A Andriulli L Solmi S Loperfido P Leo V Festa A Belmonte 2004 Prophylaxis of ERCP-related pancreatitis: A randomized, controlled trial of somatostatin and gabexate mesylate Clin Gastroenterol Hepatol 2 713-8 15290665 10.1016/S1542-3565(04)00295-2 1:CAS:528:DC%2BD2cXnt1OisLg%3D
18. J Devière OL Moine JL Van Laethem P Eisendrath A Ghilain N Severs 2001 Interleukin 10 reduces the incidence of pancreatitis after therapeutic endoscopic retrograde cholangiopancreatography Gastroenterology 120 498-505 11159890 10.1053/gast.2001.21172
19. B Murray R Carter C Imrie S Evans C O'Suilleabhain 2003 Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography Gastroenterology 124 1786-91 12806612 10.1016/ S0016-5085(03)00384-6 1:CAS:528:DC%2BD3sXlt1yrt7c%3D
20. RT Poon C Yeung CL Liu CM Lam WK Yuen CM Lo 2003 Intravenous bolus somatostatin after diagnostic cholangiopancreatography reduces the incidence of pancreatitis associated with therapeutic endoscopic retrograde cholangiopancreatography procedures: A randomized controlled trial Gut 52 1768-73 14633959 10.1136/gut.52.12.1768 1:CAS:528:DC%2BD2cXhtlSgug%3D%3D
21. H Messmann W Vogt A Holstege G Lock A Heinisch A von Fürstenberg 1997 Post-ERP pancreatitis as a model for cytokine induced acute phase response in acute pancreatitis Gut 40 80-5 9155580 1:STN:280:ByiA3c%2FlsF0%3D
22. I Honjyo K Ishii T Sato Y Goto S Naito R Mizumoto 1984 Usefulness of MR-20 in pancreatitis: A multicenter prospective randomized study (in Japanese) Igaku No Ayumi 129 70-83
23. A Saluja M Saluja A Villa U Leli P Rutledge J Meldolesi 1989 Pancreatic duct obstruction in rabbits causes digestive zymogen and lysosomal enzyme colocalization J Clin Invest 84 1260-6 2477393 1:CAS:528:DyaL1MXlvFamsrk%3D
24. ML Freeman DB Nelson S Sherman GB Haber ME Herman PJ Dorsher 1996 Complication of endoscopic biliary sphincterotomy N Engl J Med 335 909-18 8782497 10.1056/NEJM199609263351301 1:STN:280:BymA28rislE%3D
25. S Loperfido G Angelini G Benedetti F Chilovi F Costan F DeBerardinis 1998 Major early complications from diagnostic and therapeutic ERCP: A prospective multicenter study Gastrointest Endosc 48 1-10 9684657 10.1016/S0016-5107(98)70121-X 1:STN:280:DyaK1czkslOquw%3D%3D
26. E Masci G Toti A Mariani S Curioni A Lomazzi M Dinelli 2001 Complications of diagnostic and therapeutic ERCP: A prospective multicenter study Am J Gastroenterol 96 417-23 11232684 10.1111/ j.1572-0241.2001.03594.x 1:STN:280:DC%2BD3M7ot12gsQ%3D%3D
27. ML Freeman JA DiSario DB Nelson MB Fennerty JG Lee DJ Bjorkman 2001 Risk factors for post-ERCP pancreatitis: A prospective, multicenter study Gastrointest Endosc 54 425-34 11577302 10.1067/mge.2001.117550 1:STN:280:DC%2BD3Mrlt1CisA%3D%3D